- Design
- Randomised placebo-controlled trials
- Period / population
- Trials published 2025 and 2026
- Review status
- AI-assisted educational summary; no independent clinician review.
Two semaglutide trials provide encouraging alcohol-related findings in specific populations. They leave important questions about generalisability, longer-term outcomes and how the treatment fits into care.
The 2025 study
The 2025 JAMA Psychiatry trial included 48 adults with alcohol use disorder who were not seeking treatment. Over nine weeks, semaglutide reduced laboratory alcohol consumption and some weekly drinking measures. Effects were not significant for every endpoint: the study did not show a change in the number of drinking days.
A small, short study can provide a useful signal. It cannot establish long-term recovery or uncommon adverse effects across the broader population with alcohol use disorder.
What the 2026 trial added
The 2026 Lancet trial enrolled 108 treatment-seeking participants with alcohol use disorder and obesity at one centre. Both groups received cognitive behavioural therapy. At 26 weeks, the estimated between-group difference in change in heavy-drinking days favoured semaglutide by 13.7 percentage points (95% confidence interval 5.4–22.0 points). Eighty-eight participants completed the intervention; the analysis used methods to address missing data.
Gastrointestinal adverse events were more frequent with semaglutide. The population and treatment setting matter: results cannot automatically be applied to people without obesity, adolescents, pregnancy or every form of substance use disorder.
Why the two trials should not be pooled casually
| Study | Population | Duration |
|---|---|---|
| 2025 | 48 adults, not seeking alcohol treatment | 9 weeks |
| 2026 | 108 treatment-seeking adults with obesity and AUD | 26 weeks |
Different endpoints, settings and participant characteristics can change an estimate. A larger study adds information, but does not make the earlier and later populations identical. Read the primary outcome before focusing on an interesting secondary result.
What remains to be answered
- How durable are changes after treatment ends?
- Which populations benefit, and which are underrepresented?
- How does the approach compare directly with established alcohol treatments?
- What are the longer-term safety, adherence and access considerations?
These are research questions, not evidence that an answer is already known. Publication of a trial also does not establish a medicine’s regulatory indication or availability in every country.
What to discuss with a clinician
Bring questions about existing alcohol-treatment options, your health history and any medicines you already take. Do not obtain, start or alter a GLP-1 medicine on the strength of a headline. The alcohol-medication evidence guide puts established options in context.
If alcohol dependence or withdrawal is possible, ask for an assessment before abruptly stopping drinking. This research does not provide a withdrawal-management plan; see the withdrawal safety guide for when urgent care is needed.
Sources and further reading
Sources checked on 18 September 2026. Publication and data years are identified separately.
Published by AddictionResearch with AI-assisted preparation. General education; no independent clinician review is claimed.
Editorial standards Report a correction